Introduction
The tumor suppressor adenomatous polyposis coli (APC) gene is mutated in sporadic colorectal tumors and in familial adenomatous polyposis, a dominantly inherited disease characterized by multiple adenomatous polyps in the colon (Kinzler and Vogelstein, 1996; Fodde et al., 2001) . The product of the APC gene negatively regulates the Wnt-signaling pathway by inducing degradation of bcatenin (Cadigan and Nusse, 1997; Bienz and Clevers, 2000; Polakis, 2000) . Mutant APCs identified in colon cancers are defective in these activities and as a result, b-catenin levels are elevated and Wnt signaling is constitutively activated in colorectal cancer cells. Thus, the ability of APC to negatively regulate Wnt signaling is believed to be essential for its tumor suppressor function (Fodde et al., 2001 ). In addition, it has been reported that APC functions in multiple signaling pathways through interacting with various proteins, including Asef, kinesin-2, IQGAP and the human homolog of the Drosophila Discs large (hDLG) (Matsumine et al., 1996; Kawasaki et al., 2000 Kawasaki et al., , 2003 Jimbo et al., 2002; Watanabe et al., 2005; Akiyama and Kawasaki, 2006) . Inactivation of these additional APC functions might also be important for colorectal tumorigenesis.
Asef was identified as a Rac1-specific guanine-nucleotide exchange factor (GEF) that interacts with APC (Kawasaki et al., 2000) . Asef contains Dbl homology (DH), Pleckstrin (PH) and Src homology 3 (SH3) domains. The crystal structure of Asef has revealed that the SH3 and DH domains interact intramolecularly, thereby blocking the Rac1-binding site (Murayama et al., 2007) . APC binds to the NH 2 -terminal APC-binding region (ABR) of Asef via its armadillo repeat domain and enhances its GEF activity and thereby regulates cell morphology, adhesion and migration. A mutant form of Asef lacking the NH 2 -terminal ABR shows strong GEF activity even in the absence of APC, suggesting that APC may activate the GEF activity of Asef by binding to ABR and relieving negative regulation by the SH3 domain. Furthermore, truncated mutant APCs present in colorectal tumor cells activate Asef constitutively and cause decreased cell-cell adhesion and aberrant migratory properties. These findings suggest that truncated mutant APCs and Asef are important for adenoma formation and tumor progression to invasive malignancy.
In the present study, we have identified a second Asef, termed Asef2, that shows significant structural and functional similarities to Asef. We show that Asef2 acts as a GEF specific for Rac1 and Cdc42 and that its activity is enhanced by APC. Furthermore, we demonstrate that Asef2 is required for migration of colorectal tumor cells expressing truncated mutant APC. In addition, we show that Asef also exhibits GEF activity specific for Rac1 and Cdc42 in a cell type-specific manner.
Results
Our database search revealed that there are two genes, Asef2 and Collybistin I/hPEM-2, encoding proteins highly related to Asef (Figures 1a and b) . Both Asef2 and Collybistin I/hPEM-2 proteins contain DH, PH and SH3 domains. However, only Asef2 possesses a region that has amino acid homology to the ABR of Asef. Additional database search shows that the Asef2 gene generates several splicing variants containing different N-and C-terminal regions (Asef2-a, -b, -c and -d in Figure 1b ). Northern blotting analysis detected mRNAs of 8.7 kb and 6.2 kb that are expressed at high levels in human placenta, spleen and kidney, at moderate levels in lung, small intestine, liver, brain and heart, and at low levels in skeletal muscle (data not shown). Reverse transcription (RT)-PCR analysis revealed that Asef2-a and -d are expressed in colorectal epithelium (Figure 1c ). On the other hand, Asef2-b and -c were not detected. We confirmed that the Asef2-b primers are able to detect Asef2-b mRNA in SW480 cells under the same PCR conditions (data not shown).
Because Asef2 possesses an ABR domain, we examined whether Asef2 produced by in vitro translation could interact with the armadillo repeat domain of APC (APC arm) fused to glutathione-S-transferase (GST). We found that Asef2 specifically interacts with GST-APC arm, but not with GST alone (Figure 2a) . Likewise, in vitro translated APC arm interacted with GSTAsef2, but not with GST alone.
To examine whether Asef2 is associated with APC in vivo, we generated an antibody that specifically recognizes Asef2, but not Asef. When a lysate from HEK293 cells was subjected to immunoblotting with anti-Asef2 antibody, Asef2 was identified as a 170 kD protein that presumably corresponds to (Figure 2b ). When the lysate was subjected to immunoprecipitation with anti-Asef2 antibody followed by immunoblotting with anti-APC antibody, the Asef2 protein was found to co-immunoprecipitate with APC ( Figure 2b ). In these experiments, coprecipitation of Asef2 and APC was inhibited by preincubation of the antibodies with the antigens used for immunization (Figure 2b ). This shows that Asef2 and APC are contained in the same complex in vivo.
To identify the region of Asef2 responsible for its interaction with APC, we performed two-hybrid assays using various fragments of Asef2. Unexpectedly, a fragment containing the ABR domain showed no interaction with APC, whereas a fragment containing both the ABR and SH3 domains showed positive interaction (Figure 2c ). In addition, a fragment containing only the SH3 domain was negative for this interaction. These results suggest that both the ABR and SH3 domains of Asef2 are required for APC binding.
We next examined whether Asef2 functions as a GEF for RhoA, RhoG, Rac1 and/or Cdc42 in vivo. HeLa cells were transfected with HA-tagged wild type or mutant Asef2, and guanosine triphosphate (GTP)-bound RhoA, RhoG, Rac1 or Cdc42 was assayed as measures of GEF activity. We previously found that Asef-DAPC, a mutant lacking the ABR domain, possesses stronger GEF activity than wild-type Asef (Kawasaki et al., 2000) . However, because our domain analysis revealed that both ABR and SH3 domains of Asef2 are required for interaction with APC, we examined the activity of Asef2-DABR/SH3, a mutant Asef2 lacking both ABR and SH3 domains. Expression of Asef2-DABR/SH3 resulted in increases in the levels of the active forms of Rac1 and Cdc42, whereas expression of Asef2-DDH, an inactive mutant lacking the DH domain, did not (Figures 3a and b) . On the other hand, expression of Asef2-DABR/SH3 did not increase the active forms of RhoA or RhoG (Figures 3c and d ). Under these experimental conditions, the total amounts of Rac1, Cdc42, RhoA and RhoG remained constant, and each of the constructs utilized produced a protein of the expected size, although some degraded forms of Asef2-DABR/SH3 and Asef2-DDH were also detected ( Figures  3a-d) . These results suggest that Asef2 has the potential to function as a GEF specific for Rac1 and Cdc42, and that the N-terminal ABR-SH3 domain negatively regulates its GEF activity.
We previously found that truncated mutant APCs activate the GEF activity of Asef by binding to its ABR domain and relieving negative regulation. We therefore examined the effect of APC-1309, a truncated mutant APC identified in colorectal tumors, on the activity of Asef2. Expression of Asef2 along with APC-1309 resulted in increases in the levels of the active forms of Rac1 and Cdc42, whereas expression of Asef2 alone induced only a weak or undetectable increase (Figures 3a and b) . These results suggest that APC activates the GEF activity of Asef2 by binding to its NH 2 -terminal ABR and SH3 domains and relieving negative regulation.
We previously found that Asef functions as a GEF specific for Rac1. However, because Asef2 was found to activate not only Rac1 but also Cdc42 in vivo, we reexamined the specificity of Asef GEF activity. For this experiment, we used Asef-D133A/E365A, a mutant Asef in which Asp-133 and Glu-365 were replaced with Ala (Murayama et al., 2007) . These mutations abrogate the interaction between the SH3 and DH domains, and this mutant exhibited the strongest GEF activity among the series of mutants we created. Consistent with our previous findings (Murayama et al., 2007) , expression of Asef-D133A/E365A in COS-7 cells resulted in an increase in the amount of the active form of Rac1 ( Figure 3e ). By contrast, when Asef-D133A/E365A was expressed in HeLa cells, it increased the amount of the active form of Cdc42, but not Rac1 or RhoA (Figure 3f , data not shown). On the other hand, wild-type Asef barely showed any of these activities (Figures 3e and f ).
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These results suggest that similar to Asef2, Asef has the potential to function as a GEF specific for Rac1 and Cdc42 in a cell type-specific manner.
Rac1 and Cdc42 are known to be involved in the reorganization of the actin cytoskeletal network, producing lamellipodia and filopodia, respectively (van Aelst and D'Souza-Schorey, 1997; Hall, 1998) . Hence, we examined the effects of Asef2 on the morphology of MDCK and HeLa cells. When MDCK cells were transfected with full-length Asef2, they exhibited membrane ruffles and lamellipodia ( Figure 4 ). Furthermore, when MDCK cells were transfected with full-length Asef2 along with APC-1309, they became significantly enlarged and exhibited more abundant membrane ruffles and lamellipodia. Cells transfected with Asef2-DABR/SH3 also exhibited a morphology very similar to that of the Asef2-and APC-1309-transfected cells. In contrast, when similar experiments were performed with HeLa cells, cells transfected with either Asef2-DABR/ SH3 or Asef2 along with APC-1309 exhibited abundant filopodia and a few lamellipodia, while Asef2-DDH did not produce any obvious morphological change. Both Asef2 and Asef2-DABR/SH3 were found to concentrate in the lamellipodia and filopodia of MDCK and HeLa 
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Y Kawasaki et al cells, respectively. These results confirm that Asef2 activates Rac1 and Cdc42 and that its activity is regulated by APC. Because we found that Asef2 activates Rac1 and Cdc42 in a cell type-specific manner, we also examined the effect of Asef on the morphology of HeLa cells. When HeLa cells were transfected with Asef-DABR/SH3 or Asef-D133A/E365A, they exhibited abundant filopodia (Figure 4 ), suggesting that Asef could activate Cdc42 in HeLa cells. On the other hand, MDCK cells transfected with either Asef-DABR/SH3 or Asef-D133A/E365A showed abundant lamellipodia as we reported previously (Kawasaki et al., 2000) . These results further demonstrate that Asef may function as a GEF specific for Rac1 and Cdc42 in a cell type-specific manner.
Asef is known to play an important role in the regulation of cell migration. Thus, we examined the effects of Asef2 on MDCK cell motility using a Transwell migration chamber. When MDCK cells were transfected with Asef2, they showed increased motility as compared to mock-transfected cells (Figure 5a ). Cells transfected with Asef2-DABR/SH3 showed further enhanced migratory activity. On the other hand, overexpression of Asef2-DDH did not promote migration of MDCK cells. These results suggest that Asef2, like Asef, has the potential to promote cell migration.
Truncated mutant APCs present in colorectal tumor cells activate Asef constitutively and cause aberrant migratory properties (Kawasaki et al., 2003) . We examined whether Asef2 is also involved in aberrant migration of colorectal tumor cells. We expressed short hairpin RNA (shRNA), shRNA-Asef2, designed to suppress Asef2 expression, and examined its effect on the migratory activity of SW480 cells. We also performed control experiments with point mutant shRNA, mut-shRNA-Asef2. Cells expressing shRNA-Asef2 showed decreased motility as compared to mut-shRNAAsef2-transfected cells (Figure 5b ). Immunoblotting analysis revealed that expression of Asef2 is almost completely inhibited in shRNA-Asef2-transfected cells, but not in mut-shRNA-Asef2-transfected cells (Figure 5c ). These results suggest that the mutant APC and Asef2 are important for the migration of SW480 cells. 
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Discussion
In the present study, we have shown that Asef2 activates Rac1 and Cdc42 in vivo and that its activity is enhanced by truncated mutant APC expressed in colorectal tumor cells. Consistent with this finding, truncated mutant APC stimulated Asef2-mediated lamellipodia formation in MDCK cells and filopodia formation in HeLa cells. In addition, we have shown that Asef is also able to activate not only Rac1, but also Cdc42 and induce lamellipodia and filopodia formation in a cell typespecific manner. Our findings suggest that Asef and Asef2 could function as GEFs specific for Rac1 and Cdc42. However, it has been reported that dimeric Cool-2/a-Pix acts as a Rac-specific GEF, but its monomeric form acts as a GEF for Cdc42 as well as for Rac upon the binding of PAK or Cbl to its SH3 domain (Feng et al., 2004) . Therefore, it is also possible that the specificity of Asef and Asef2 GEF activity is changed by regulation of the monomer-dimer equilibrium, interaction with other molecules or post-translational modification in vivo.
During the preparation of this manuscript, Hamann et al. (2007) have also identified and characterized Asef2 and reported that Asef2 and Asef function as GEFs specific for Cdc42 both in vitro and in vivo. Also, Gotthardt and Ahmadian (2007) have reported that Asef functions as a GEF for Cdc42, but not for Rac1 in in vitro GEF assays. The reasons for this discrepancy are not clear, but may be due to the differences in the materials and conditions used for the GEF assays. In our previous study (Kawasaki et al., 2000) , Asef-DAPC and Asef stimulated with APC arm exhibited GEF activity for Rac1 when we used certain lots of recombinant Rac1 generated by the baculoviral system. However, they did not show GEF activity against recombinant Rac1 generated by the bacterial system. On the other hand, we examined Asef GEF activity against Cdc42 using recombinant Cdc42 generated by the bacterial system. This could be a reason why Asef did not show GEF activity against Cdc42 in our previous study. Although Hamann et al. (2007) reported that Asef and Asef2 activate only Cdc42, but not Rac1 in vivo, this could be because they used cell lines suitable for Cdc42 activation.
We recently solved the three dimensional structure of Asef and found that the SH3 domain interacts intramolecularly with the DH domain, and this interaction 
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Y Kawasaki et al autoinhibits Asef GEF activity (Murayama et al., 2007) . Furthermore, we found that the RT-loop and the C-terminal region of the SH3 domain interact with the DH domain in a manner completely different from those for canonical binding to a polyPro-peptide motif. This autoinhibition by the Asef SH3 domain is relieved by APC binding to the Asef ABR domain (Kawasaki et al., 2000) . We unexpectedly found that both the ABR and SH3 domains of Asef2 are required for APC binding. However, similar to Asef, APC binding to the Asef2 ABR and SH3 domains enhanced Asef2 GEF activity. Furthermore, a mutant form of Asef2 lacking the ABR and SH3 domains exhibited strong GEF activity even in the absence of APC. Thus, the structural mechanism of the intramolecular GEF inhibition by the SH3 domain may be conserved in Asef2, and APC binding to the Asef2 ABR and SH3 domains may result in relief of this autoinhibition mechanism. The functions of the N-terminal regions of Asef2 variants (for example, Asef2-c and -d, see Figure 1 ) remain to be examined. We showed previously that the APC-Asef complex functions in cell migration, and that Asef activated by truncated mutant APCs present in colorectal tumor cells contributes to their aberrant migratory properties.
Similarly, we have found that overexpression of Asef2 promotes migration of MDCK cells. Furthermore, RNA interference experiments showed that Asef2 is also required for the migration of colorectal tumor cells expressing truncated APC. These results suggest that in addition to the APC-Asef complex, the APC-Asef2 complex may play an important role in cell migration, and that Asef2 as well as Asef activated by truncated mutant APC contributes to the aberrant migratory properties of colorectal tumor cells. Our hypothesis seems to be consistent with previous reports showing that forced expression of APC induces disordered cell migration in the intestinal epithelium (Wong et al., 1996) and that inactivation of APC completely abrogates migration along the cryptvillus axis (Sansom et al., 2004) . It was also reported that the proliferation rate of early adenoma cells in APC knockout mice is similar to that of the normal crypt epithelium, but adenoma cells lack directed migration along the crypt-villus axis (Oshima et al., 1997) . In addition to the role of Asef and Asef2 in tumorigenesis, it would also be interesting to identify the signaling pathway(s) that regulates the function of the APC-Asef2 complex. 
Materials and methods
Expression vectors and antibodies
The human Asef2 cDNA clone KIDNE2003373 was obtained from the Helix Research Institute and subcloned into the mammalian expression vector pcDNA3.1( þ ) (Invitrogen, Carlsbad, CA, USA). Mutant Asef2s were generated by PCR. Mouse monoclonal antibody (mAb) against APC was raised against a peptide containing residues 119-250 of APC. Polyclonal antibodies (pAbs) to APC and Asef2 were prepared by immunizing rabbits with peptide containing amino acids 1122-1729 of APC and 1-137 of Asef2-b, respectively. Antibodies were purified by affinity chromatography using columns to which the antigens used for immunization had been linked. Rabbit pAb to the Myc tag (polyclonal version of 9E10) and a rat mAb to the HA tag (3F10) were obtained from Medical & biological Laboratories (MBL) and Roche (Palo Alto, CA, USA) , respectively. A mouse mAb against FLAG tag and a mAb to a-tubulin was from Sigma (St Louis, MO, USA) and Oncogene Research (San Diego, CA, USA), respectively.
Cell culture and transfection MDCK, HEK293 and COS-7 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum (FCS). HeLa cells were cultured in minimum essential medium supplemented with 10% FCS and 0.1 mM nonessential amino acids. Plasmids were transfected into these cells using Lipofectamine 2000 (Invitrogen) or Fugene (Roche).
RT-PCR
Total RNA was extracted from human colorectal epithelium, and first-strand cDNA was synthesized using random hexamers and Superscript III reverse transcriptase (Invitrogen). PCR reactions were performed in 20 ml volumes and amplified for 5 min at 941C for initial denaturation, followed by 45 cycles at 941C for 1 min, 571C for 1 min and 721C for 1 min. This reaction was followed by a final elongation step that lasted 7 min at 721C. The primer sequences used were as follows, Asef2-a forward primer:
0 -CCTGGAAGCCACACATGGTGATGAGG-3 0 and common reverse primer: 5 0 -CACATGGTCCCACAGGGCTTCT GCGC-3 0 . Although Asef2-b was not detected in colorectal epithelium (Figure 1c) , the Asef2-b primers were able to detect Asef2-b mRNA in SW480 cells (data not shown).
In vitro binding assay [ 35 S]Methionine-labeled APC arm and full-length Asef2-a were synthesized by in vitro transcription translation using the TNT-coupled reticulocyte lysate system (Promega, Madison, WI, USA). Proteins fused to GST were synthesized in Escherichia coli and isolated by absorption to GSH-Sepharose (Amersham Biosciences, Little Chalfont, Buckinghamshire, UK). GST and GST-fusion proteins (2 mg) immobilized to beads were incubated with in vitro translation products in binding buffer (0.1% NP-40, 50 mM HEPES (pH 7.0), 150 mM NaCl, 50 mM NaF, 5 mM ethylenediaminetetraacetic acid, 1 mM dithiothreitol, 1 mg/ml aprotinin, 1 mg/ml leupeptin, 50 mg/ml p-amidinophenylmethanesulfonyl fluoride hydrochloride) and then washed extensively with binding buffer. Proteins adhering to the beads were analysed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by autoradiography. Two-hybrid system, immunoprecipitation and immunoblotting Two-hybrid system, immunoprecipitation and immunoblotting analysis were performed as described previously (Kawasaki et al., 2000) .
GTPase activation assays
After 24 h of transfection, cells were lysed in buffer containing 2% octylphenoxy poly (ethyleneoxy) ethanol (IGEPAL), 50 mM Tris-HCl (pH 7.5), 10 mM MgCl 2 and 0.3 M NaCl. To detect the active GTP-bound form of GTPases in the cell lysates, the supernatants were mixed with 50 mg of recombinant GST-PAK-CRIB (for Rac1 and Cdc42), GST-Rhoteckin RBD (for RhoA) and GST-RhoGIP122 (for RhoG) bound to glutathione-Sepharose beads for 1 h. The beads and the proteins bound to the fusion protein were washed two times with wash buffer containing 25 mM Tris-HCl (pH 7.5), 30 mM MgCl 2 and 40 mM NaCl, and then the bound proteins Lysates prepared from transfected cells were analysed by immunoblotting with anti-Asef2 antibody. Anti-a-tubulin antibody was used as a control.
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Immunostaining Cells were fixed with 3.7% formaldehyde in PBS for 1 h, permeabilized with 0.2% Triton X-100/PBS for 5 min and stained with anti-HA mAb alone or double stained with anti-HA mAb and anti-Myc pAb for 60 min at room temperature. Staining patterns obtained with these antibodies were visualized by incubation with Alexa Fluor 488-conjugated goat antirat IgG or Alexa Fluor 594-conjugated goat anti-rabbit IgG for 60 min at room temperature. Cells were photographed with a Carl Zeiss LSM510 laser microscope.
shRNAs DNA oligonucleotides encoding shRNAs were subcloned into the U6 promoter vector, pSHAG-1. The sequences of the region targeted for shRNAs in the human Asef2 cDNA was 5 0 -TGAAATAGGATCTTGCTTTCTTCAAAATCAA-3 0 . The sequences of mut-shRNA-Asef2 was 5 0 -TGAAATAAGATCT TGATTTCTTTAAAATCAA-3 0 .
Cell migration assays
Cell migration assays were performed in Transwell migration chambers (diameter 6.5 mm; pore size 8 mm; Costar Corporation, Cambridge, MA, USA) as described (Kawasaki et al., 2003) . After 24 h of transfection, MDCK cells (5.0 Â 10 3 cells per well) were added to the upper compartment of the Transwell chamber and allowed to migrate to the underside of the top chamber for 24 h. For SW480 cells, the underside of the membrane was coated with 10 mg/ml fibronectin. SW480 cells transfected with shRNA-Asef2 along with a puromycin resistance gene plasmid (molar ratio 3:1) were cultured for 48 h in the presence of puromycin (3.5 mg/ml), and surviving cells were used for migration assays. Cell migration was determined by counting the cells that migrate to the lower side of the polycarbonate filters.
